Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.


  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Global therapeutic IPO market: Q3 2017 analysis

The global therapeutic IPO market has failed to maintain the upward momentum established throughout a busy Q2 2017, with just over $1 billion raised by 13 drug development companies during Q3. Whilst this marks a 52% decrease in the frequency of IPOs and a 65% decrease in funds raised when compared to Q2 2017, year-to-date analysis highlights that the IPO market has markedly improved when compared to the same period in 2016. From Q1 through to Q3 2017, a total of 52 IPOs have raised over $4.35 billion, representing a 13% increase in the frequency of IPOs and a staggering 121% increase in funds raised when compared to the same time period in 2016. Globally, therapeutic companies remain heavily focused on listing in the United States, with many international companies foregoing local exchanges in favour of the NASDAQ market.

Regional focus: Americas

A total of nine companies floated on the NASDAQ during Q3 2017, raising a combined total of $892.1 million. The trend of global companies electing to list on American markets instead of local exchanges continued in Q3 2017, with Edinburgh-based NuCana and Oxford University spinout Nightstar Therapeutics opting to list on the NASDAQ, raising $100 million and $75 million, respectively. Clementia Pharmaceuticals, a Canadian company that is focused on treating rare bone diseases, raised a total of $120 million through its NASDAQ IPO.

Compared to Q2 2017, there has been a 14% decrease in the total amount raised and a 36% decrease in the frequency of drug development IPOs on the NASDAQ. The largest IPO this quarter was Shanghai-based Zai Lab, which raised $150 million on the NASDAQ to fund the continued development of its pipeline of small molecule drugs to treat cancer, autoimmune and infectious diseases.

Regional focus: Europe

Whilst it was a quiet quarter for therapeutic listings on the EURONEXT, ESM, AIM/LSE, SIX and Deutsche Borse, the NASDAQ OMX/First North market continues to impress, with three successful biopharma IPOs in Q3 2017. Of the three successful OMX IPOs, Danish drug developer Zealand Pharma raised the most funds ($78.2 million) to support its pipeline of peptide-based medicines to treat type-2 diabetes, hypoglycaemia and short bowel syndrome. Swedish company Xspray Pharma, which develops cancer drugs based on protein kinase inhibitors, successfully raised $16.42 million; whilst Promore Pharma, a Swedish company developing therapeutic peptides for bioactive wound care, raised $9.2 million.

Regional focus: APAC

South Korean antibody developer AbClon was the sole drug development IPO on an APAC-based exchange during Q3 2017, raising $6.13 million on the KOSDAQ market to support its preclinical mAb targeting epidermal growth factor (EGF).

Whilst WuXi Biologics successfully raised over $511 million through a massive IPO on the Hong Kong stock exchange, the company has been excluded from Evolution Global’s analysis as it is a contract services provider that does not develop its own therapeutics. In contrast, Samsung Biologics was included in previous analysis as it does develop its own drug candidates.

Trends and conclusions

Small Molecule therapeutics remain the dominant treatment type for drug development companies that have gone public in 2017. Of the 13 companies that IPO’d this quarter, five companies are primarily focused on the development of oncology therapeutics.

Whilst therapeutic IPO activity has declined significantly when compared to Q2 2017, overall the IPO market has improved significantly when compared to 2016. This historical data collected by Evolution Global highlights that despite a quarter-over-quarter decrease in both frequency and funds raised, the therapeutic IPO market has actually improved when compared with 2016.

This article is comprised of selected data from Evolution Bioscience’s exclusive Therapeutic IPO Data Visualisation, which compiles global market data from 2012 onwards, offering a comprehensive historical analysis of trends in biopharmaceutical drug development. View the fully-interactive data visualisation by clicking on the button below:



Written By

Evolution provide elite executive search solutions for the biotechnology, biopharmaceutical and related industries. We specialise in delivering bespoke solutions to an exclusive cohort of reputable clients, from leading university spinout providers through to blue chip multinationals.


Add Your Response